Trending Now
Promising Developments in Waldenstrom Macroglobulinemia Treatment: Mustang Bio’s Latest Clinical Trial...
Mustang Bio, Inc. (Nasdaq: MBIO), a trailblazer in clinical-stage biopharmaceuticals, is making significant strides in cell therapy treatments aimed at curing challenging...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Lineage Cell Therapeutics Inc. (NYSEAMERICAN:LCTX) Endorses Proposition 14 and Announces...
Lineage Cell Therapeutics Inc. (NYSEAMERICAN:LCTX) has endorsed the recently passed proposition 14 in California.
Lineage endorses the passing of...
MAKE IT MODERN
LATEST REVIEWS
Novan Inc (NASDAQ:NOVN) Phase 3 Clinical Study Of Antiviral Gel –...
Novan Inc (NASDAQ:NOVN) commenced a double-blind, multi-center, vehicle-controlled, and randomized Phase 3 clinical study of SB206 to cure molluscum (molluscum contagiosum). It opened clinical...
MAKE IT MODERN
PERFORMANCE TRAINING
Denali Therapeutics Inc. (NASDAQ: DNLI) To Present Posters for DNL310 Clinical Study Program At...
Denali Therapeutics Inc. (NASDAQ: DNLI) has revealed upcoming presentations from the DNL310 (ETV: IDS) clinical development initiative to be issued virtually and at the...
Harmonic Inc (NASDAQ: HLIT) Announces $2.1 Million in Income During The Second Quarter of...
Harmonic Inc (NASDAQ: HLIT) recently announced its unaudited results in 2Q2021. The company reported a revenue of $113.4 million, a 53% year-over-year increase.
Financial summary
According...
Baudax Bio Inc (NASDAQ: BXRX) Issues an Update on Its Novelty Drug ANJESCO
Baudax Bio Inc (NASDAQ: BXRX) recently announced its intention to begin a clinical study investigating whether the administration of pharmacokinetics injections in minors between...
Qualigen Therapeutics Inc. ((NASDAQ: QLGN) Announce Global In-License for QN-302 For Treatment of Pancreatic...
Qualigen Therapeutics Inc. (NASDAQ: QLGN) has announced an exclusive global in-license of genomic quadruplex (G4) selective transcription inhibitor development program that includes preclinical data,...
Dynavax Technologies Corporation (NASDAQ:DVAX)’s Collaboration with Mount Sinai to Develop a Universal Influenza (Flu)...
Dynavax Technologies Corporation (NASDAQ:DVAX), a vaccine-focused biopharma will be collaborating with the Icahn School of Medicine at Mount Sinai. Their collaboration will lead to...
MAKE IT MODERN
